Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Kidney fibrosis is mediated by GARP-restricted TGF-β activation in fibroblasts
Yintong Chen, Weiwei Xu, Jieli Yu, Pei Deng, Nianping Liu, Yinyin Li, Hui Zhou, Hong Zhou, Jianchuan Wang, Bo Zhao, Florian Winau, Fan Fan Hou, Yu Hu
Yintong Chen, Weiwei Xu, Jieli Yu, Pei Deng, Nianping Liu, Yinyin Li, Hui Zhou, Hong Zhou, Jianchuan Wang, Bo Zhao, Florian Winau, Fan Fan Hou, Yu Hu
View: Text | PDF
Research Article Nephrology Public Health

Kidney fibrosis is mediated by GARP-restricted TGF-β activation in fibroblasts

  • Text
  • PDF
Abstract

TGF-β is a central driver of kidney fibrosis, a common pathological hallmark of chronic kidney disease (CKD). Initiation of TGF-β signaling requires not only its synthesis but also the conversion of latent TGF-β to its bioactive form. However, the mechanisms governing TGF-β activation in the kidney and their contribution to kidney fibrosis remain poorly understood. Glycoprotein A repetitions predominant (GARP) anchors latent TGF-β on the cell surface and facilitates its bioactive release. Here, we show that GARP-mediated TGF-β activation promotes kidney fibrosis. GARP was upregulated in both human and mouse CKD kidneys, predominantly in fibroblasts, and was induced by TNF in an NF-κB–dependent fashion. In multiple mouse models of kidney fibrosis, either global or fibroblast-specific deletion of GARP markedly reduced fibrosis. Mechanistically, GARP enables sustained production of active TGF-β, thereby amplifying fibroblast stimulation. Deletion of GARP in kidney fibroblasts lowered active TGF-β levels and attenuated fibroblast activation, whereas GARP overexpression enhanced TGF-β signaling. Notably, tamoxifen-induced deletion of GARP after fibrosis onset attenuated kidney fibrosis. Together, our findings identify GARP-mediated release of active TGF-β as a critical step in sustaining fibroblast activation during kidney fibrosis and highlight GARP as a promising therapeutic target for CKD.

Authors

Yintong Chen, Weiwei Xu, Jieli Yu, Pei Deng, Nianping Liu, Yinyin Li, Hui Zhou, Hong Zhou, Jianchuan Wang, Bo Zhao, Florian Winau, Fan Fan Hou, Yu Hu

×

Figure 6

TNF upregulates GARP in an NF-κB–dependent fashion and synergizes with TGF-β1.

Options: View larger image (or click on image) Download as PowerPoint
TNF upregulates GARP in an NF-κB–dependent fashion and synergizes with T...
(A) Venn diagram of transcription factors predicted to bind to the Lrrc32 promoter region using ChEA and JASPAR tools. (B) Gene set enrichment analysis (GSEA) of fibroblasts from human kidney single-cell transcriptomic data (GSE183279) comparing CKD and reference samples, showing significant positive enrichment of the Hallmark TNFA signaling via NF-κB gene set in CKD fibroblasts. (C and D) mRNA (C) and protein (D) levels of GARP in NRK-49F cells treated with TNF (10 ng/mL) for the indicated durations. (E–G) mRNA (E) and protein (F and G) levels of GARP in TNF-stimulated NRK-49F cells in the absence or presence of PDTC (an NF-κB inhibitor). Representative images and quantitative analysis are shown in E and F, respectively. (H) The NF-κB consensus motif is shown at the top, and the gray regions mark 2 potential NF-κB binding sites (NBS1 and NBS2) in the rat Lrrc32 promoter. (I) ChIP analysis of NF-κB p65 binding to NBS1 and NBS2 in the rat Lrrc32 promoter and to the distal Lrrc32 enhancer in NRK-49F cells under basal or TNF-stimulated conditions. Normal IgG served as a control. (J–L) mRNA (J) and protein (K and L) levels of GARP in NRK-49F cells treated with TGF-β1 (2 ng/mL) for the indicated durations. Representative images and quantitative analysis are shown in J and K, respectively. (M and N) mRNA (M) and protein (N) levels of GARP in NRK-49F cells treated with TNF, TGF-β1, or the combination of TGF-β1 and TNF. All in vitro experiments were independently repeated 3 times with similar results. Data represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Statistical significance was determined by 1-way ANOVA (C, E, G, J, L, M) or 2-way ANOVA (I) with Tukey’s test for multiple comparisons.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts